Zhaoke clears once-nightly cyclosporine dry-eye gel in China—three years after a withdrawn NDA and too late for 2026 NRDL

Zhaoke Ophthalmology (06622.HK) won China NMPA approval on Nov 10 for once-nightly Cyclosporine Ophthalmic Gel (Jingyouling) after Phase 3 COSMO, facing a self-pay 2027 race against Xingqi (300573.SZ).

Zhaoke clears once-nightly cyclosporine dry-eye gel in China—three years after a withdrawn NDA and too late for 2026 NRDL
Formulation, trial, and 2027 reimbursement comparison between Zhaoke's Jingyouling gel and Shenyang Xingqi's incumbent Zirun eye drops.

Chapter 18A biotech Zhaoke Ophthalmology Limited (HKEX: 06622) announced on November 13, 2026 that China’s National Medical Products Administration (NMPA) approved its self-developed Cyclosporine Ophthalmic Gel (Jingyouling) on November 10 to increase tear production in patients with dry eye disease. Disclosed in an evening inside-information filing (06622.HK, 18:41 HKT), the decision closes a three-year regulatory detour after Zhaoke voluntarily withdrew its initial NDA in October 2023 and refiled in May 2025 (CXHS2500052). Because the clearance arrived four months after the National Healthcare Security Administration (NHSA) cut unapproved pre-applicants from the 2026 National Reimbursement Drug List (NRDL) formal review, Zhaoke must spend 2027 pitching a self-pay once-nightly gel against Shenyang Xingqi Ophthalmic’s (SZSE: 300573) NRDL-reimbursed twice-daily cyclosporine drops (Zirun).

From a 2023 NDA withdrawal to COSMO’s two-week onset claim

Jingyouling is China’s first approved ophthalmic hydrogel formulation of cyclosporine and Zhaoke’s first internally developed innovative drug to reach the market. Combining nanomicellar solubilization with a preservative-free mucoadhesive hydrogel, the formulation extends corneal residence time so patients dose once daily at bedtime rather than twice daily during waking hours.

Zhaoke originally completed its 41-center, 644-patient Chinese Phase 3 COSMO trial earlier in the decade, only to withdraw its first NDA in October 2023 after CDE updated its technical review expectations for dry-eye endpoints. Following additional post-hoc analyses, pre-NDA consultations with CDE, and initiation of a supplementary 360-patient Chinese Phase 3 study (NCT06766357), NMPA re-accepted the NDA in May 2025—one month before the U.S. FDA cleared Zhaoke’s Phase 3 IND using the Chinese COSMO package as supportive evidence.

In COSMO (n = 644 moderate-to-severe dry eye patients randomized to once-nightly gel or vehicle), the approved dataset showed:

  • Primary Day-84 sign endpoint: 73.7% of patients on Cyclosporine Ophthalmic Gel achieved a ≥1-point improvement from baseline in Inferior Corneal Staining Score (ICSS), compared with 53.2% on vehicle control (P < 0.0001).
  • Two-week onset: Statistically significant separation over vehicle emerged by Day 14 (P < 0.05) across ICSS, Oxford corneal/conjunctival staining, and anesthetized Schirmer tear production, sustained through Day 84—contrasting with the four-to-eight-week lag typical of conventional cyclosporine emulsions.
  • Ocular tolerability: Treatment-related ocular adverse events occurred in 12.5% of gel recipients versus 5.4% on vehicle, led by transient eye pain (8.1%, with all other ocular reactions below 3%) and zero drug-related serious adverse events.

The 2027 commercial fault line: bedtime convenience vs. NRDL coverage

Winning NMPA approval solves Zhaoke’s regulatory overhang, but the timing creates an immediate reimbursement asymmetry across Chinese ophthalmology clinics and e-commerce pharmacies:

Commercial Dimension Zhaoke (06622.HK) — Jingyouling Gel Shenyang Xingqi (300573.SZ) — Zirun Drops
Formulation & schedule Preservative-free nanomicellar hydrogel; once nightly at bedtime 0.05% single-use nanoemulsion (0.4 mL: 0.2 mg); twice daily, 12h apart
China approval & patent Approved November 10, 2026 (first domestic CsA gel) Approved June 2020 (composition patent to July 2039)
2027 reimbursement status Out-of-pocket / commercial only (dropped from July 14, 2026 NHSA final review list) NRDL Class B (“restricted to dry eye disease,” renewed in 2025 NRDL Notice No. 33)

Earlier this summer, Zhaoke attempted to bridge that gap using NHSA’s pre-application (yushenbao) channel for pending NDAs, passing preliminary June screening; however, because final NMPA sign-off did not land before NHSA’s mid-July verification cutoff, Jingyouling was one of 18 outside-catalogue pre-applicants excluded from the final July 14, 2026 formal review roster.

Per Zhaoke’s 2026 interim report (06622.HK), first-half product revenue stood at just RMB 17.6 million (approx. $2.4 million) against a RMB 122.6 million net loss, supported by RMB 715.8 million (approx. $99.4 million) in unpledged cash and term deposits (plus RMB 295.6 million in pledged bank balances) and four commercial lines at its Guangzhou Nansha plant, which also won Australian TGA GMP certification on October 27. Until Zhaoke enters the mid-2027 NRDL negotiation cycle, commercial traction will depend on out-of-pocket retail pricing, online prescription channels, and upcoming NMPA decisions on its two other filed flagship drugs—low-dose atropine (NVK002) and ophthalmic bevacizumab (TAB014)—alongside Gulf Cooperation Council (GCC) review in Saudi Arabia.